Stefania De Lorenzo
Università degli Studi di Bologna
H-index: 17
Europe-Italy
Top articles of Stefania De Lorenzo
The impact of etiology on patterns of progression of advanced HCC
Digestive and Liver Disease
2024/2/1
Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: data from a multicenter collaborative study
Digestive and Liver Disease
2024/2/1
Management of portal hypertension in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma
Digestive and Liver Disease
2024/2/1
The synergic effect of metformin with atezolizumab/bevacizumab in masld hcc patients: a retrospective study from arte multicentric Italian dataset
Digestive and Liver Disease
2024/2/1
Aetiology of hepatocellular carcinoma and response to immunotherapy: is the problem inherent in the classification of non-viral disease?
Digestive and Liver Disease
2024/2/1
Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study
BJS open
2024/2
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Life
2023/11/6
Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma
Digestive and Liver Disease
2023/9/1
P-94 Overview of clinicopathological and prognostic factors for long-term survivors of pancreatic cancer from a multicenter study of 532 patients
Annals of Oncology
2023/6/1
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
British Journal of Cancer
2023/3/23
Mariacristina Di Marco
H-Index: 23
Guido Giordano
H-Index: 22
Mario Scartozzi
H-Index: 33
Stefania De Lorenzo
H-Index: 10
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
Current Oncology
2023/2/22
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma.
2022/9/23
A novel prognostic tool in western and eastern biliary tract cancer patients treated in first-line setting: the ECSIPOT index
Journal of Gastrointestinal Cancer
2022/9
Giovanni Brandi
H-Index: 35
Mario Scartozzi
H-Index: 33
Changhoon Yoo
H-Index: 23
Hyungwoo Cho
H-Index: 6
Stefania De Lorenzo
H-Index: 10
Jae Ho Jeong
H-Index: 8
Small bowel adenocarcinoma: from molecular insights to clinical management
2022/2/17
Stefania De Lorenzo
H-Index: 10
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
Liver International
2022/2
Francesco Tovoli
H-Index: 23
Francesco Caputo
H-Index: 27
Stefania De Lorenzo
H-Index: 10
Alessandro Granito
H-Index: 34
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study
2022/1/2
Giorgio Frega
H-Index: 8
Stefania De Lorenzo
H-Index: 10
Davide Melisi
H-Index: 27
Giovanni Brandi
H-Index: 35
Massimo Dominici
H-Index: 41
Should patients on levothyroxine therapy be screened for pancreatic cancer?
Acta Biomed
2022
Stefania De Lorenzo
H-Index: 10
Paolo Del Rio
H-Index: 12
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
Anti-Cancer Drugs
2022/1/1
Giovanni Brandi
H-Index: 35
Stefania De Lorenzo
H-Index: 10
Stefano Brocchi
H-Index: 4
Giorgio Frega
H-Index: 8
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
ESMO open
2021/10/1
Targeted therapies for gallbladder cancer: An overview of agents in preclinical and clinical development
2021/7/3
Stefania De Lorenzo
H-Index: 10
Francesco Tovoli
H-Index: 23
